Lenvima 4 mg

LENVIMA 4 MG capsules contain lenvatinib mesylate, a targeted therapy used in cancer treatment. This oral medication is designed to inhibit tumor growth and may be prescribed for specific types of cancer.

LENVIMA 4 MG capsules are primarily used in the treatment of certain types of cancer. Lenvatinib mesylate works by targeting specific proteins involved in tumor growth and blood vessel formation. This medication may be prescribed for conditions such as thyroid cancer or renal cell carcinoma, but the exact use should be determined by a healthcare professional based on individual patient needs.

Common effects of LENVIMA 4 MG capsules may include fatigue, hypertension, diarrhea, and decreased appetite. Some individuals may also experience nausea, vomiting, or changes in taste. It is important to discuss any persistent or severe side effects with a healthcare provider.

LENVIMA 4 MG capsules should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions.

LENVIMA 4 MG capsules may interact with certain medications, including those that are metabolized by the liver. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Additionally, alcohol consumption should be discussed with a healthcare provider, as it may affect the efficacy or safety of the medication.